Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the ...
Citius Oncology, Inc. (Nasdaq: CTOR) is a commercial-stage biopharmaceutical company headquartered in Cranford, New Jersey, dedicated to advancing targeted oncology treatments. The company's primary asset is LYMPHIR (denileukin diftitox), an investigational orphan drug that received FDA approval for the treatment of adults with relapsed or refractory Stage I–III cutaneous T-cell ...Citius Oncology, Inc. (Nasdaq: CTOR) is a commercial-stage biopharmaceutical company headquartered in Cranford, New Jersey, dedicated to advancing targeted oncology treatments. The company's primary asset is LYMPHIR (denileukin diftitox), an investigational orphan drug that received FDA approval for the treatment of adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL) who have had at least one prior systemic therapy. LYMPHIR is designed to target cancer cells expressing the IL-2 receptor, offering a novel therapeutic option for a rare and difficult-to-treat disease.
Following FDA approval, Citius Oncology launched LYMPHIR commercially in December 2025 and reported initial revenue of $3.9 million for that month, marking a significant milestone. The company is a subsidiary of Citius Pharmaceuticals, Inc., leveraging its parent's research and development capabilities. Financially, the company has a market capitalization of approximately $67.9 million as of the latest data, with a negative price-to-earnings ratio due to ongoing investments in commercialization and R&D. The company's enterprise value stands at $69.0 million, and it has incurred operating losses typical for a biopharmaceutical startup, with an EBITDA margin of -7.32 and a net profit margin of -7.58.
Key personnel include CEO Leonard L. Mazur, who also serves as Chief Executive Officer of Citius Pharmaceuticals. The company has a small workforce, with less than 100 employees, reflecting its early-stage commercial operations. Citius Oncology focuses on building a portfolio of targeted oncology therapies, with plans to expand its pipeline and continue advancing research. The company's strategic priorities include maximizing LYMPHIR's market penetration, exploring additional indications, and pursuing partnerships to broaden its impact in oncology. With a strong pipeline and a recent commercial launch, Citius Oncology aims to establish itself as a leader in targeted cancer treatments.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
-10.4%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-24.8M
-17.1%
+66.5%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
-159.9%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
+66.0%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
+62.6%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-5.5M
-4446.7%
+28.2%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
+19.9%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
8.5%
+2.8%
+134.6%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
0.56x
+65.9%
+45.2%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
